Regarding the somatostatin receptor 2 (SSTR2) status, 90% of evaluated NET G3 patients were SSTR-positive (n = 19) on immunohistochemistry, whereas only 66% of NEC patients were immunohistochemically positive (n = 19). Here, SSTR2 is linked to neuroendocrine carcinoma.